Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Neuroectodermal Tumors, Primitive 2Neoplasms 2Uterine Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Perivascular Epithelioid Cell Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Hamartoma Syndrome, Multiple 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Diseases 1Angiomyolipoma 1Advanced Solid Tumor 1

Interventions

Everolimus 6Cannabidiol 6radiprodil 3ganaxolone 3Sirolimus 2Melatonin 2exemestane 1dactolisib 1Solutions 1Itraconazole 1Injections 1Carbamazepine 12-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Tuberous Sclerosis × dactolisib × Clear all
NCT01690871 2013-08-02

A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa

Novartis

Phase 2 Withdrawn

Tuberous Sclerosis, Angiomyolipoma, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡